Sponsored Content | Whitepapers | Magnetic Resonance Imaging (MRI) | February 19, 2016

GenIQ, A Quantified Analysis to Assess Vascular Properties in Lesions


Learn more about GenIQ, a new post-processing application for assessing the vascular properties of brain, liver, prostate and breast tumors for initial as well as follow-up examinations.

To download the white paper, click here.

Related Content

Vista.ai appoints MedTech veteran Daniel Hawkins President and
News | Radiology Business
Vista.ai Appoints MedTech Veteran Daniel Hawkins as Chief Executive Officer

April 17, 2024 — VISTA.AI announced the appointment of Daniel Hawkins as President and CEO. The company is pioneering AI ...

Time April 17, 2024
arrow
Collaboration set to deliver comprehensive navigation and imaging integration that will streamline intraoperative decision-making
News | Radiology Business
Brainlab and Fujifilm Integrate Cutting-Edge Technology, Offering Advanced Capabilities to Neurosurgery Clinicians in the US

April 4, 2024 — FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging ...

Time April 04, 2024
arrow
During the blood pool phase, it significantly shortens the T1 and T2 relaxation times of the blood, thus achieving bright blood effects in T1-weighted imaging and dark blood effects in T2/T2*-weighted imaging. In the delay phase, by the local aggregation of ferumoxytol disrupting the uniformity of the local magnetic field, the decrease of the transverse magnetization vector Mxy is expedited, resulting in a negative contrast effect.
News | Molecular Imaging
Exploring Ferumoxytol: A Frontier in MRI Contrast Agents

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
SyntheticMR announced today that their next-generation imaging solution with isotropic resolution, SyMRI 3D, has received FDA 510(k) clearance for clinical use in the United States
News | FDA
SyntheticMR Receives FDA 510(k) Clearance for its Next Generation Solution SyMRI 3D

March 27, 2024 — SyntheticMR announced that its next-generation imaging solution, SyMRI 3D, has received FDA 510(k) ...

Time March 27, 2024
arrow
Innovative Smart Quant Neuro 3D technology provides auto measurement of various brain tissues to enhance decision support of brain disease, assess progression and monitor the effect of therapy
News | Artificial Intelligence
Philips Teams with Synthetic MR to Deliver Breakthrough AI-based Quantitative Brain Imaging in MR to Advance Neurology Care for Patients at #ECR2024

March 1, 2024 — Royal Philips, a global leader in health technology, and magnetic resonance imaging (MRI) software ...

Time March 01, 2024
arrow
85-year-old patient with ischemic heart disease, who underwent cardiac MRI at 3 T
News | Cardiac Imaging
Free-breathing DL vs. Breath-hold Cardiac MRI Sequences in Ischemic Heart Disease

February 12, 2024 — According to the American Journal of Roentgenology (AJR), free-breathing cine-deep learning (DL) may ...

Time February 12, 2024
arrow
Franco Fontana
News | Radiology Business
Esaote Unveils its New Brand Identity at 2024 Worldwide Sales and Marketing Meeting, Florence

January 25, 2024 — Esaote Group, a leading Italian innovator in medical imaging, today unveiled its new brand identity ...

Time January 25, 2024
arrow
Quibim announced it has added an industry-leading cancer detection capability to its prostate tool based on artificial intelligence (AI).
News | Artificial Intelligence
Quibim Adds Cancer Detection Capability to Prostate AI Product

January 23, 2024 — Quibim announced it has added an industry-leading cancer detection capability to its prostate tool ...

Time January 22, 2024
arrow
Product significantly improves patient outcomes by enabling earlier diagnosis
News | Artificial Intelligence
Quibim’s AI-based Early-stage Neurological Disease Quantification Software for Quantification of Early Brain Atrophy and Lesions Authorized for Use in US, EU and UK

December 22, 2023 — Quibim, a company pioneering imaging biomarkers for Precision Medicine that has created AI-based ...

Time December 22, 2023
arrow
Terran Biosciences, Inc., a biotech platform company developing therapeutics and technologies for patients with neuropsychiatric illnesses, has received FDA clearance to market NM-101
News | Magnetic Resonance Imaging (MRI)
Terran Biosciences Receives FDA Clearance for NM-101, the Industry’s First Software for the Analysis of Neuromelanin-sensitive MRI

December 20, 2023 — Terran Biosciences, Inc., a biotech platform company developing therapeutics and technologies for ...

Time December 20, 2023
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now